(UroToday.com) Enzalutamide is an approved drug in the United States for the treatment of metastatic hormone-sensitive prostate cancer based on the phase three ARCHES study (NCT02677896)1 and supported by the phase 3 ENZAMET trial (NCT02446405).2 Both these trials demonstrated improved clinical outcomes, including radiographic progression-free survival and overall survival with enzalutamide versus the comparator arm.